Global Predictive Presymptomatic Testing Market 2024-2028

Global Predictive Presymptomatic Testing Market 2024-2028

Global Predictive Presymptomatic Testing Market 2024-2028

The predictive presymptomatic testing market is forecasted to grow by USD 2594.7 mn during 2023-2028, accelerating at a CAGR of 10.03% during the forecast period. The report on the predictive presymptomatic testing market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing healthcare spending worldwide, increasing demand for genetic counseling, and rise in awareness toward early screening of genetic disorders.

Technavio's predictive presymptomatic testing market is segmented as below:

• By Application
• Cancer diseases
• Genetic diseases
• Cardiovascular diseases
• By Geographical Landscape
• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the growing prevalence of genetic diseases as one of the prime reasons driving the predictive presymptomatic testing market growth during the next few years. Also, rise in awareness toward early screening of genetic disorders and advancements in genetic testing techniques will lead to sizable demand in the market.

The report on the predictive presymptomatic testing market covers the following areas:

• Predictive presymptomatic testing market sizing
• Predictive presymptomatic testing market forecast
• Predictive presymptomatic testing market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading predictive presymptomatic testing market vendors that include 23andMe Holding Co., Abbott Laboratories, Amgen Inc., BioAxis DNA Research Centre P Ltd., Color Health Inc., Deep Genomics Inc., Direct Laboratory Services LLC, DNA and U, Editas Medicine Inc., Healius Ltd., Illumina Inc., International Business Machines Corp., Mapmygenome India Ltd., myDNA Life Ltd., Myriad Genetics Inc., NeoGenomics Laboratories Inc., Quest Diagnostics Inc., Sysmex Corp., and Veritas Genetics Inc.. Also, the predictive presymptomatic testing market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.